Effectiveness of Scolopendrid Pharmacopuncture for Neuropathic Dysfunction: Clinical Evidence and Potential Mechanism

TL;DR

This paper reviews how Scolopendrid venom, used in a traditional Korean therapy called pharmacopuncture, may help treat nerve-related pain and dysfunction.

Contribution

The paper provides a comprehensive review of the clinical and experimental evidence supporting the use of Scolopendrid pharmacopuncture for neuropathic conditions.

Findings

Scolopendrid pharmacopuncture reduces neuropathic pain by modulating ion channels and inflammatory pathways in animal models.

Clinical studies show efficacy in treating pain from conditions like Bell’s palsy and carpal tunnel syndrome.

Safety and toxicity profiles of Scolopendrid venom remain insufficiently studied.

Abstract

Animal venoms, particularly Scolopendrid venom, have gained significant attention as therapeutic agents in complementary and alternative medicine, especially for applications in pain management and neuroprotection. In traditional Korean medicine, Scolopendrid venom is administered through pharmacopuncture, a method that combines injection therapy with principals of acupuncture. The present review focuses on the multifaceted effects of Scolopendrid pharmacopuncture, derived from Scolopendra polymorpha, on the peripheral nervous system, and its potential role in addressing the neuropathic dysfunction that often arises from peripheral nerve injuries. Scolopendrid venom exhibits various pharmacological properties, including analgesic, anti-inflammatory, and neuroprotective effects. Experimental studies have shown that Scolopendrid pharmacopuncture significantly reduces neuropathic pain in animal models by modulating ion channels and inflammatory pathways. Clinical investigations have further revealed its efficacy in alleviating pain associated with conditions such as Bell’s palsy and carpal tunnel syndrome. Despite its promising therapeutic potential, the lack of comprehensive clinical research on the toxicity and safety profiles of SPP remains a critical limitation. Future studies should focus on evaluating the safety of Scolopendrid venom as a standalone treatment and incorporate broader data sources to enhance our understanding of its implications in clinical practice.